Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results.
Identifieur interne : 002C10 ( Main/Exploration ); précédent : 002C09; suivant : 002C11Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results.
Auteurs : RBID : pubmed:16314738English descriptors
- KwdEn :
- Adult, Aged, Cell Line, Tumor, Female, Heterocyclic Compounds (diagnostic use), Heterocyclic Compounds (pharmacokinetics), Humans, Indium Radioisotopes (diagnostic use), Male, Melanoma (metabolism), Melanoma (pathology), Melanoma (radionuclide imaging), Middle Aged, Neoplasm Staging, Octreotide (analogs & derivatives), Octreotide (chemistry), Octreotide (diagnostic use), Octreotide (pharmacokinetics), Peptides, Cyclic (diagnostic use), Peptides, Cyclic (pharmacokinetics), Radionuclide Imaging (methods), Radiopharmaceuticals (diagnostic use), Radiopharmaceuticals (pharmacokinetics), Receptors, Somatostatin (metabolism), Tumor Cells, Cultured.
- MESH :
- chemical , analogs & derivatives : Octreotide.
- chemical , chemistry : Octreotide.
- chemical , diagnostic use : Heterocyclic Compounds, Indium Radioisotopes, Octreotide, Peptides, Cyclic, Radiopharmaceuticals.
- chemical , metabolism : Receptors, Somatostatin.
- chemical , pharmacokinetics : Heterocyclic Compounds, Octreotide, Peptides, Cyclic, Radiopharmaceuticals.
- metabolism : Melanoma.
- methods : Radionuclide Imaging.
- pathology : Melanoma.
- radionuclide imaging : Melanoma.
- Adult, Aged, Cell Line, Tumor, Female, Humans, Male, Middle Aged, Neoplasm Staging, Tumor Cells, Cultured.
Abstract
The overexpression of somatostatin receptors (SST-Rs) on various tumour cells provides the molecular basis for the successful use of radiolabelled SST analogues in clinical oncology. The objective of the study was to evaluate the tumour binding of In-1,4,7,10-tetraazacyclo-dodecane-N,N',N'',N'''-tetraacetic acid-lanreotide (In-DOTA-LAN) and In-DOTA-tyrosine-octreotide (In-DOTA-Tyr-OCT) in patients with stage IV melanoma. In addition, we evaluated the potential antiproliferative effect of SST analogues, together with an assessment of the functionality of SST-Rs, on four melanoma cell lines. Twenty-three patients with advanced metastatic melanoma underwent scintigraphy. Thirty-eight of 61 lesions (62%) were positively imaged with In-DOTA-LAN, whereas 23 (37%) were negative. With In-DOTA-Tyr-OCT, 10 of the 23 documented lesions (43%) were positive and 13 (56%) were negative. In vitro, cell lines showed no growth inhibition in the presence of SST analogues and no influence on cell cycle distribution was found with the addition of SST analogues to cultured cells. In addition, no functional surface SST-Rs could be demonstrated on these cell lines. Taken together, our results demonstrate the visualization of metastatic melanoma in a high percentage of patients, probably due to binding of SST analogues to SST-Rs on tumour vessels or infiltrating immune cells. Judging from our data, however, there is no evidence of functional SST-R expression on melanoma cells.
PubMed: 16314738
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results.</title><author><name sortKey="Valencak, Julia" uniqKey="Valencak J">Julia Valencak</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Medical University of Vienna, Vienna, Austria. julia.valencak@meduniwien.ac.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Dermatology, Medical University of Vienna, Vienna</wicri:regionArea></affiliation></author><author><name sortKey="Heere Ress, Elisabeth" uniqKey="Heere Ress E">Elisabeth Heere-Ress</name></author><author><name sortKey="Traub Weidinger, Tatjana" uniqKey="Traub Weidinger T">Tatjana Traub-Weidinger</name></author><author><name sortKey="Raderer, Markus" uniqKey="Raderer M">Markus Raderer</name></author><author><name sortKey="Schneeberger, Achim" uniqKey="Schneeberger A">Achim Schneeberger</name></author><author><name sortKey="Thalhammer, Theresia" uniqKey="Thalhammer T">Theresia Thalhammer</name></author><author><name sortKey="Aust, Sylvia" uniqKey="Aust S">Sylvia Aust</name></author><author><name sortKey="Hamilton, Gerhard" uniqKey="Hamilton G">Gerhard Hamilton</name></author><author><name sortKey="Virgolini, Irene" uniqKey="Virgolini I">Irene Virgolini</name></author><author><name sortKey="Pehamberger, Hubert" uniqKey="Pehamberger H">Hubert Pehamberger</name></author></titleStmt><publicationStmt><date when="2005">2005</date><idno type="RBID">pubmed:16314738</idno><idno type="pmid">16314738</idno><idno type="wicri:Area/Main/Corpus">002D19</idno><idno type="wicri:Area/Main/Curation">002D19</idno><idno type="wicri:Area/Main/Exploration">002C10</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Cell Line, Tumor</term><term>Female</term><term>Heterocyclic Compounds (diagnostic use)</term><term>Heterocyclic Compounds (pharmacokinetics)</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Male</term><term>Melanoma (metabolism)</term><term>Melanoma (pathology)</term><term>Melanoma (radionuclide imaging)</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (chemistry)</term><term>Octreotide (diagnostic use)</term><term>Octreotide (pharmacokinetics)</term><term>Peptides, Cyclic (diagnostic use)</term><term>Peptides, Cyclic (pharmacokinetics)</term><term>Radionuclide Imaging (methods)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Radiopharmaceuticals (pharmacokinetics)</term><term>Receptors, Somatostatin (metabolism)</term><term>Tumor Cells, Cultured</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Heterocyclic Compounds</term><term>Indium Radioisotopes</term><term>Octreotide</term><term>Peptides, Cyclic</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Heterocyclic Compounds</term><term>Octreotide</term><term>Peptides, Cyclic</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radionuclide Imaging</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Cell Line, Tumor</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Tumor Cells, Cultured</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The overexpression of somatostatin receptors (SST-Rs) on various tumour cells provides the molecular basis for the successful use of radiolabelled SST analogues in clinical oncology. The objective of the study was to evaluate the tumour binding of In-1,4,7,10-tetraazacyclo-dodecane-N,N',N'',N'''-tetraacetic acid-lanreotide (In-DOTA-LAN) and In-DOTA-tyrosine-octreotide (In-DOTA-Tyr-OCT) in patients with stage IV melanoma. In addition, we evaluated the potential antiproliferative effect of SST analogues, together with an assessment of the functionality of SST-Rs, on four melanoma cell lines. Twenty-three patients with advanced metastatic melanoma underwent scintigraphy. Thirty-eight of 61 lesions (62%) were positively imaged with In-DOTA-LAN, whereas 23 (37%) were negative. With In-DOTA-Tyr-OCT, 10 of the 23 documented lesions (43%) were positive and 13 (56%) were negative. In vitro, cell lines showed no growth inhibition in the presence of SST analogues and no influence on cell cycle distribution was found with the addition of SST analogues to cultured cells. In addition, no functional surface SST-Rs could be demonstrated on these cell lines. Taken together, our results demonstrate the visualization of metastatic melanoma in a high percentage of patients, probably due to binding of SST analogues to SST-Rs on tumour vessels or infiltrating immune cells. Judging from our data, however, there is no evidence of functional SST-R expression on melanoma cells.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16314738</PMID><DateCreated><Year>2005</Year><Month>11</Month><Day>29</Day></DateCreated><DateCompleted><Year>2006</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0960-8931</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Melanoma research</Title><ISOAbbreviation>Melanoma Res.</ISOAbbreviation></Journal><ArticleTitle>Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results.</ArticleTitle><Pagination><MedlinePgn>523-9</MedlinePgn></Pagination><Abstract><AbstractText>The overexpression of somatostatin receptors (SST-Rs) on various tumour cells provides the molecular basis for the successful use of radiolabelled SST analogues in clinical oncology. The objective of the study was to evaluate the tumour binding of In-1,4,7,10-tetraazacyclo-dodecane-N,N',N'',N'''-tetraacetic acid-lanreotide (In-DOTA-LAN) and In-DOTA-tyrosine-octreotide (In-DOTA-Tyr-OCT) in patients with stage IV melanoma. In addition, we evaluated the potential antiproliferative effect of SST analogues, together with an assessment of the functionality of SST-Rs, on four melanoma cell lines. Twenty-three patients with advanced metastatic melanoma underwent scintigraphy. Thirty-eight of 61 lesions (62%) were positively imaged with In-DOTA-LAN, whereas 23 (37%) were negative. With In-DOTA-Tyr-OCT, 10 of the 23 documented lesions (43%) were positive and 13 (56%) were negative. In vitro, cell lines showed no growth inhibition in the presence of SST analogues and no influence on cell cycle distribution was found with the addition of SST analogues to cultured cells. In addition, no functional surface SST-Rs could be demonstrated on these cell lines. Taken together, our results demonstrate the visualization of metastatic melanoma in a high percentage of patients, probably due to binding of SST analogues to SST-Rs on tumour vessels or infiltrating immune cells. Judging from our data, however, there is no evidence of functional SST-R expression on melanoma cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valencak</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Affiliation>Department of Dermatology, Medical University of Vienna, Vienna, Austria. julia.valencak@meduniwien.ac.at</Affiliation></Author><Author ValidYN="Y"><LastName>Heere-Ress</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Traub-Weidinger</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Raderer</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schneeberger</LastName><ForeName>Achim</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Thalhammer</LastName><ForeName>Theresia</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Aust</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Virgolini</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Pehamberger</LastName><ForeName>Hubert</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Melanoma Res</MedlineTA><NlmUniqueID>9109623</NlmUniqueID><ISSNLinking>0960-8931</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Heterocyclic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Peptides, Cyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium 111-DOTA-lanreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>octreotide, DOTA-Tyr(3)-</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Heterocyclic Compounds</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Melanoma</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">chemistry</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Peptides, Cyclic</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radionuclide Imaging</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">00008390-200512000-00007</ArticleId><ArticleId IdType="pubmed">16314738</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C10 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C10 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16314738
|texte= Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16314738" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |